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Several studies have implicated the angiogenic cytokine
vascular endothelial growth factor (VEGF) in the
development of diabetic nephropathy, but no data are
available about its local activity during human disease.
Glomeruli from 52 archival biopsies from type II diabetics
were evaluated and compared to 10 renal biopsies without
kidney disease (controls). Glomerulosclerosis, capillary
rarefaction, glomerular and endothelial cell proliferation,
apoptosis, VEGF expression, as well as receptor-bound VEGF
indicating local VEGF activity, and phosphorylation of the
signal transduction molecule Akt were investigated. Owing to
substantial heterogeneity of glomerular lesions in individual
biopsies, these parameters were correlated with the degree
of injury in individual glomeruli rather than biopsies. Severe
glomerular capillary rarefaction was linked to the degree of
glomerulosclerosis. While cellular apoptosis was detected
independent of the stage of injury, endothelial cell
proliferation indicating capillary repair was markedly
increased only in mildly/moderately injured glomeruli. In
controls, VEGF was predominantly expressed in podocytes,
whereas receptor-bound VEGF was confined to the
glomerular endothelium. VEGF expression was increased in
all diabetic glomeruli by many different cell types. In contrast,
VEGF receptor activation was increased predominantly in the
endothelium of only mildly injured glomeruli, but
significantly decreased in more severely injured glomeruli.
Diabetic nephropathy is associated with glomerular capillary
rarefaction. Despite overall increased glomerular VEGF, the
decreased receptor-bound VEGF on the endothelium may be
an indicator of an insufficient capillary repair reaction.
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Diabetes is the leading cause of renal failure in the western
world.1 About 30–40% of all diabetics develop signs of
diabetic nephropathy and thereby have a very high risk for
chronic renal failure requiring renal replacement therapy. In
addition, micro- and macrovascular diabetic complications
are associated with highly increased morbidity and mortality.
Diabetic nephropathy is characterized by structural changes
of glomeruli including hypertrophy, matrix expansion, base-
ment membrane thickening, formation of nodules, and
obsolescence of the capillary tuft. Most of these changes
during diabetic nephropathy have been shown to be modu-
lated by cytokines such as transforming growth factor beta,
angiotensin II, nitric oxide, as well as vascular endothelial
growth factor (VEGF).2
VEGF is a major angiogenic cytokine3 and mediates
angiogenesis during many physiological and pathophysio-
logical processes.4 The importance of VEGF has also been
demonstrated during various experimental renal diseases
including diabetic nephropathy.5–8
Within the human kidney, VEGF is strongly expressed in
podocytes and also in proximal and distal tubular cells,9–11
while the two most extensively described VEGF receptors
(VEGF-Rs) fms-like tyrosine kinase (VEGF-R1) and fetal
liver kinase 1 (VEGF-R2) are predominantly expressed on the
endothelium of glomeruli, pre- and postglomerular vessels
but also to a lesser extent on mesangial cells and tubular
cells.9,12
Experimental studies inhibiting VEGF via blocking
antibodies revealed an important deleterious role of VEGF
in the pathophysiology of diabetic nephropathy.5,6,13 In
several models of diabetic nephropathy, VEGF and VEGF
receptors are consistently increased in the kidney, especially
early in the course of disease.14 Previous studies in humans
demonstrated increased VEGF or VEGF mRNA in mild
changes of diabetic nephropathy, but inconclusive data on
its regulation during later stages (either unchanged or
increased).10,15–17
While several VEGF isoforms exist and are differentially
regulated regarding their release or sequestration in the
extracellular matrix or at the cellular surface,14 the direct
detection of receptor-bound VEGF via specific antibodies
reflects local VEGF activity.18 These antibodies were raised in
mice against the NH2 terminus of VEGF and recognize a
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conformational epitope that is created in consequence to
VEGF receptor binding. This antibody has been shown to
identify proliferating tumor vessels and can bind to both
VEGF–VEGF-R1 (fms-like tyrosine kinase ) and VEGF–-
VEGF-R2 (fetal liver kinase 1) complexes.18,19
The present study was performed to further investigate the
expression and for the first time the local activity of VEGF in
comparison to its potential effect on angiogenesis as assessed
by glomerular capillary rarefaction as well as endothelial cell
proliferation/apoptosis during human type II diabetic
nephropathy. Despite a consistent upregulation of VEGF
during all phases of injury in type II diabetic nephropathy,
receptor-bound/active VEGF was only increased in
mildly, but not in more severely injured glomeruli.
Considering the progressive glomerular capillary rarefaction
during diabetic nephropathy, the decreased VEGF activity
may be an indicator of an insufficient capillary repair
reaction as supported by low and decreasing rates of
endothelial cell proliferation in more severely diseased
diabetic glomeruli.
RESULTS
The clinical disease stage did not correlate with histological
findings during diabetic nephropathy
The study included a total number of 52 biopsies with type II
diabetic nephropathy containing a total number of 575
glomeruli. Owing to missing material, periodic acid-Schiff
stain staining was not evaluated for two diabetic kidney
biopsies. The mean age of all patients was 62.778.8 years, the
10 non-diabetic patients without evidence of renal disease
(non-diabetic controls) had a mean age of 46.7722 years
(Table 1). The male/female ratio between the 52 patients and
the 10 control subject was slightly different (1.5:1 vs 1:1).
Whereas non-diabetic controls had normal serum creatinine
and urea levels (Table 1), renal function of diabetic patients
was markedly decreased (serum creatinine 3.272.3 mg/dl,
urea 116771 mg/dl). In more than one-third of all 52
diabetic patients, evidence for other diabetic complications
such as retinopathy or neuropathy was present (Table 1). The
diagnosis of diabetic nephropathy is usually made without a
renal biopsy. Most diabetic patients referred to our clinic for
renal biopsy either had some unclear worsening of renal
function, proteinuria or newly diagnosed nephrotic syn-
drome, or even a nephritic syndrome. Therefore, most
diabetic patients of this study were classified into clinical
stage IV of diabetic nephropathy (also called overt nephro-
pathy) and no correlations between the clinical disease stage
and histological findings could be detected. In addition,
no correlations between other clinical parameters (Table 1)
and histological findings such as glomerulosclerosis or
tubulointerstitial fibrosis were detected.
Glomerulosclerosis and capillary loss are increased and
closely linked during diabetic nephropathy
Several studies in glomerulonephritis20 have demonstrated a
link between capillary loss and progressive glomerulosclero-
sis, suggesting a causal role for capillary rarefaction in
progressive kidney disease. Therefore, these parameters were
investigated in renal biopsy specimens from patients with
diagnosed diabetic nephropathy. In kidney biopsies without
evidence of specific renal disease, glomerulosclerosis score
was low with 0.9470.65. Compared to these biopsies,
glomerulosclerosis score was markedly increased to
3.470.53 (Po0.05 for all groups) in patients with diabetic
nephropathy. In parallel, the glomerular capillary rarefaction
score increased from 1.1770.1 in controls to 2.8670.63 in
diabetic disease. Both parameters (glomerulosclerosis and
capillary rarefaction) closely related to each other in
individual patients as demonstrated by a Pearson’s coefficient
of r¼ 0.55 (Po0.001; Figure 1). In parallel, the tubulointer-
stitial injury score was markedly increased in patients with
diabetic nephropathy (2.070.6) compared to tissue speci-
mens without evidence of renal disease (0.370.5; Po0.001).
Peritubular capillary rarefaction score was markedly elevated
in diabetic kidneys (73.976.3) compared to tissues without
Table 1 | Baseline parameters of diabetic and non-diabetic
patients and presence of relevant diabetic complications
Parameter
Diabetes group
mean7s.d.
Non-diabetic
controls
mean7s.d.
Age (years) 62.778.8 46.7722 NS
Male/female ratio 1.5:1 1:1
Duration of diabetes (years) 12.877.8 Not present
Proteinuria (mg/dl) 436075257 Not present
Albuminuria (mg/dl) 316376737 Not present
HbA1c level (mg/dl) 6.872.1 Not present
Serum creatinine (mg/dl) 3.272.3 0.970.3
Serum urea (mg/dl) 116771 31712
Presence of retinopathy (n) 23 Not present
Presence of diabetic neuropathy (n) 19 Not present
Presence of hypertension (n) 20 Not present
HbA1c, hemoglobin A1c; NS, not significant.
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Figure 1 | Glomerular capillary loss and glomerulosclerosis are
linked during development of diabetic nephropathy. Glomerulo-
sclerosis was assessed on periodic acid-Schiff stain-stained sections
and scored from 0 to 4 as described in the Materials and Methods
section. Glomerular capillary rarefaction was assessed also using a
scoring system from 0 to 4 after staining for PECAM-1/CD31. In
individual patients, glomerulosclerosis and glomerular capillary
rarefaction were closely linked (r¼ 0.55; Po0.001).
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evidence of renal disease (53.9710.4; Po0.001). Both
findings indicate that diabetic kidneys have severe tubulo-
interstitial lesions. In contrast to glomerular diabetic
lesions, peritubular capillary rarefaction and tubulointersti-
tial injury did not correlate with each other. Since histology
of type II diabetic glomerulopathy is heterogeneous with
mildly and severely injured glomeruli coexisting in the same
section even next to each other and pathophysiology may
differ depending on the stage of injury, we evaluated every
single glomerulus according to its morphological integrity as
mildly (I), moderately (II), or severely injured (III). Hereby,
43 diabetic glomeruli could be characterized as stage I, 170
diabetic glomeruli as stage II, and 362 diabetic glomeruli as
stage III.
Endothelial cell proliferation is increased in mild to
moderate, but not severe diabetic lesions
Glomerular capillary preservation is balanced by both
endothelial cell proliferation and apoptosis. Therefore,
cellular proliferation in glomeruli with and without diabetic
kidney disease was assessed by staining against the Ki-67
antigen (Figure 2a). The number of Ki-67-positive glomer-
ular cells was increased in all diabetic glomeruli vs undiseased
glomeruli (no evidence of renal disease (nrd)¼ 0.0570.36;
I¼ 0.2270.59, II¼ 0.2870.59; III¼ 0.271.0; (n) all
Po0.001), while the number of proliferating cells in severely
injured glomeruli (III) was lower than in moderately injured
glomeruli (II; Figure 2a). To further investigate specifically
glomerular capillary repair and EC proliferation, a double
staining against the Ki-67 antigen for proliferating cells and
platelet-endothelial cell adhesion molecule-1 (PECAM-1)/
CD31 for glomerular endothelial cells was performed (Figure
2b and c). EC proliferation was significantly increased in
diabetic glomeruli with mild (I¼ 0.3370.56 (n); Po0.001)
and moderate (II¼ 0.3570.59 (n); Po0.001) injury com-
pared to kidneys without evidence of renal disease
(nrd¼ 0.0470.09 (n)) (Figure 2b). However, in glomeruli
with severe (III) injury, endothelial cell proliferation
(0.0970.32 (n)) was markedly decreased compared to
glomeruli with a lower degree of injury (Iþ II: Po0.001)
and close to the EC proliferation rate in glomeruli of the nrd
group (Figure 2b). Figure 2c shows an example of the Ki-67/
PECAM-1 double staining where originally Ki-67-positive
cells are red and PECAM-1-positive endothelium is brown
(visible as prominent dark cell). Since apoptosis indicates
glomerular injury and counteracts cellular proliferation, we
also investigated whether this parameter might be modulated
during diabetic nephropathy. Whereas the degree of apop-
tosis was not significantly different from glomeruli without
evidence of disease (nrd: 0.02770.016 (n)) to mildly injured
glomeruli (I: 0.04570.021 (n)), the degree of apoptosis was
increased in glomeruli with moderate injury (II: 0.1270.33
(n) both Po0.05) and showed a strong tendency in severely
injured glomeruli (III: 0.170.3 (n); P¼ 0.59; Figure 2d).
Thereby the balance of endothelial repair vs injury progres-
sively decreased from milder towards more severe lesions as
indicated by the ratio of proliferating glomerular endothelial
cells to glomerular apoptotic cells (Figure 2e).
Since VEGF is the major angiogenic cytokine, we
examined whether VEGF expression or VEGF activity might
be regulated during capillary rarefaction in diabetic nephro-
pathy.
During diabetic glomerulopathy, various glomerular cell
types are positive for VEGF, whereas receptor-bound VEGF is
largely restricted to glomerular endothelial cells
Consistent with earlier studies, VEGF staining in biopsies
without apparent renal disease was mainly localized in
podocytes (Figure 3a; arrow). In addition, some minimal
VEGF immunostaining was also detected in the mesangial
area. In glomeruli with mild (I) diabetic injury (Figure 3b),
the expression pattern of VEGF markedly changed. In
addition to podocytic staining, VEGF could be detected in
glomerular endothelial cells (small image shows a zoomed
capillary loop and a podocyte positive for VEGF) as well as in
the mesangial area. Glomeruli with enhanced injury and
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Figure 2 | Glomerular endothelial cell proliferation is increased
during diabetic nephropathy. Glomerular proliferation was
assessed by the number of Ki-67 antigen (a proliferation marker)-
positive cells per glomerular cross-section (gcs) (a). Both, Ki-67- and
PECAM-1/CD-31 (a marker for endothelial cells)-positive cells as
assessed by double staining characterize proliferating endothelial
cells in glomeruli (b), which were significantly increased during
diabetic glomerulopathy. (c) An example of this double staining
technique, where originally Ki-67-positive cells are marked in red and
PECAM-1 positive cells are brown (here visible as prominent dark
cell). A double-stained proliferating endothelial cell is depicted
as a zoomed image. (d) The number of apoptotic cells per gcs as
assessed by terminal deoxynucleotidyl transferase (TdT)-mediated
dUTP-biotin nick end labelling staining (d). (e) The ratio of
proliferating glomerular endothelial cells to glomerular apoptotic
cells per gcs indicates the balance of endothelial repair vs injury.
(nrd: no evidence of renal disease; I, II, III: glomerular injury
according to Table 2; *Po0.05 compared to nrd; Po0.05 compared
to termed groups).
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fibrosis (II and III) demonstrated a strongly enhanced
staining as seen in glomeruli with a typical Kimmelstiel–-
Wilson lesion, whereas typical nodules were completely
negative for VEGF (Figure 3c).
Staining patterns of receptor-bound VEGF using a specific
monoclonal antibody against the VEGF–VEGF-R complex19
were clearly different. In renal biopsies without evidence of
disease (Figure 3d), as well as in mildly (Figure 3e) or severely
(Figure 3f) injured glomeruli, receptor-bound VEGF was
predominantly restricted to glomerular endothelial cells
indicating the specific activation of VEGF receptors on
glomerular endothelial cells. At a next step, quantitative
analysis of immunostaining for VEGF and receptor-bound
VEGF was performed.
During diabetic glomerulopathy, expression, receptor
binding, and activation of VEGF are differentially regulated
Quantitative analysis of VEGF staining (Figure 4a) in
glomeruli of diabetic kidneys clearly demonstrated overall
increased expression in glomeruli with diabetic lesions (stage
I¼ 8.775; II¼ 10.476; III¼ 10.176.9% positive area)
compared to biopsies without evident renal disease (nrd:
2.672.2% positive area; all Po0.001). No significant
difference could be found between the different degrees of
glomerular injury. In contrast, receptor-bound VEGF as
assessed by specific staining against the VEGF–VEGF-R
complex was differentially regulated dependent on the stage
of injury during diabetic nephropathy. Compared to biopsies
without renal disease (nrd: 12.775.8% positive area),
receptor-bound VEGF was significantly increased only in
glomeruli with mild injury (I¼ 16.477% positive area;
Po0.001; Figure 4b). In contrast, glomeruli with moderate
and severe injury demonstrated significantly lower amounts
of receptor-bound VEGF (II¼ 1175.8% positive area;
III¼ 10.876.9% positive area) when compared to mildly
injured glomeruli (Po0.001) or even glomeruli from kidneys
without renal disease (IIþ III: Po0.001). To further assess
whether a similar pattern can be seen at the VEGF-VEGF-R-
induced signal transduction level, we investigated the down-
stream phosphorylation of Akt. Nuclear detection of
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Figure 3 | VEGF is expressed by various glomerular cell types
during diabetic nephropathy, whereas VEGF directly bound to its
receptor is almost completely confined to the glomerular
endothelium. VEGF staining was performed using an antibody
detecting all VEGF isoforms. (a) An example of the VEGF staining in
kidneys without renal disease, where VEGF is mainly restricted to
podocytes (arrows). In glomeruli with mild to moderate diabetic
injury (b), VEGF can be detected in various cell types such as
endothelial cells (smaller image shows a zoomed capillary loop),
mesangial cells, as well as round, mononuclear cells (e.g. mono-
cytes–macrophages) and podocytes. In severely injured glomeruli
(c), VEGF is frequently expressed by almost all glomerular cell types
and the normal podocytic expression pattern is completely lost.
Interestingly, Kimmelstiel–Wilson noduli are completely devoid of
VEGF, but surrounded by VEGF-positive cells. In contrast to VEGF
expression, VEGF directly bound to its receptors reflecting VEGF
action demonstrated a predominant and typical endothelial pattern
within glomeruli of both without (d) and with diabetic kidney disease
(e), although some staining could also be seen in other glomerular
cell types. The most prominent endothelial staining pattern was
found in mildly injured glomeruli (e), whereas in more severely
injured glomeruli, the staining pattern of receptor-bound VEGF lost
its clearcut endothelial pattern, was more diffuse, and even
compared to normal glomeruli clearly reduced (f).
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Figure 4 | VEGF expression and VEGF-R binding are differentially
regulated during diabetic glomerulopathy and result in en-
hanced Akt phosphorylation. Glomerular immunostainings of VEGF
and the VEGF–VEGF-R complex were evaluated using computer-
assisted morphometry and independently scored according to their
degree of glomerular injury. Whereas VEGF was upregulated during
all stages of glomerular injury (a), VEGF-R binding was differentially
regulated (b). Mildly injured glomeruli demonstrated increased VEGF-
R binding, whereas more severely injured glomeruli demonstrated
decreased VEGF–VEGF-R complexes compared to normal and mildly
injured glomeruli, respectively (b). Phosphorylated Akt-positive cells
per glomerular cross-section (gcs) were evaluated by counting Akt-
positive cells in all glomeruli and independently scored according to
their degree of glomerular injury (c). Enhanced Akt phosphorylation
could frequently be detected in endothelial cells (arrows), and also in
some other glomerular cells (d). (nrd: no evidence of renal disease;
I, II, III: glomerular injury according to Table 2; *Po0.05 compared to
nrd; Po0.05 compared to termed groups).
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phosphorylated Akt was significantly enhanced in glomeruli
with mildly (I: 52.9715 (n); Po0.001) and moderately
injured glomeruli (II: 33.3712.3 (n); Po0.001) compared to
glomeruli without evidence of disease (nrd: 5.773 (n)) and
beneath levels of glomeruli without renal disease in severely
injured glomeruli (III: 9.778.2 (n); Figure 4c). Figure 4d
depicts that many nuclei of endothelial cells (arrows) but also
some other glomerular cells are phosphorylated Akt (p-Akt)
positive. The degree of Akt phosphorylation (Figure 4c)
parallels the proliferative response of endothelial cells (Figure
2b) and is similar, but not identical to VEGF bound to its
receptors (Figure 4b). This may relate to the fact that p-Akt
cannot be considered to be absolutely VEGF receptor specific
and that the p-Akt antibody detects all three phosphorylated
forms of Akt.
DISCUSSION
In the present study, we investigated renal biopsies from
patients with type II diabetic nephropathy regarding glomer-
ular capillary repair and qualitative as well as quantitative
expression and activity patterns of the major angiogenic
cytokine VEGF. Diabetic nephropathy is the most common
single cause of renal insufficiency in man.1 Early morpho-
logical and morphometrical studies have demonstrated that
basement membrane thickening, glomerular (and renal)
hypertrophy, as well as matrix deposition within diabetic
glomeruli followed by progressive glomerular sclerosis
including Kimmelstiel–Wilson noduli are characteristic for
diabetic nephropathy.21,22 While most of these studies were
performed in type I diabetics, these findings have been widely
accepted as hallmarks during type II diabetic nephropathy as
well.23 Glomerular hyperfiltration and microalbuminuria are
the earliest clinical signs for ongoing diabetic renal injury and
reflect the early changes of renal hemodynamics and
alterations to the glomerular filter.24
Several growth factors and cytokines have been implicated
in the mediation of these diabetic glomerular changes.
Angiogenic factors are secreted in response to endothelial
dysfunction caused by hyperglycemia, oxidative stress, and
inflammation on microvascular endothelial cells.24 During
development of proliferative diabetic retinopathy, a central
role for an underlying endothelial injury and the actions of
VEGF as a major mediator of micro-/macrovascular
hyperpermeability and endothelial cell proliferation were
recognized.25 Recent experimental studies support an im-
portant role of hyperglycemia-driven secretion of VEGF also
during diabetic nephropathy.26 VEGF-blocking studies de-
monstrated that the inhibition of VEGF might prevent the
development of diabetic nephropathy.5 These beneficial
results from a VEGF-blocking therapy seem to be specific
for diabetic nephropathy, since experimental studies in
several other glomerular diseases showed harmful effects
via a VEGF blockade and beneficial effects via VEGF
treatment.27,28
In the present study, we demonstrate that similar to other
glomerular diseases,27,28 glomerular capillary rarefaction is an
important feature of disease progression also during ongoing
diabetic injury and correlates with the degree of glomerular
sclerosis. In parallel, peritubular capillary rarefaction is also
markedly enhanced in diabetic kidneys supporting the role of
capillary loss for the disease progression even though the
present study was not able to demonstrate a direct link
to tubulointerstitial fibrosis in individual patients. This
indicates that there might be an imbalance between
endothelial cell injury and repair during diabetic nephro-
pathy at least in regard to the glomerular capillary tuft. The
balance between endothelial proliferation and apoptosis was
reduced in more severe compared to milder lesions,
suggesting insufficient capillary repair as a cause for the pro-
gression of diabetic nephropathy. From experimental studies
during glomerulonephritis,20 cell proliferation is known as
one of the most important endothelial repair mechanisms.29
VEGF is an important mitogen and survival factor for
endothelial cells thereby contributes to angiogenesis and
repair after injury.27
Therefore in this study, the expression and even the local
activity of VEGF in biopsies of type II diabetic patients was
evaluated and related to the capillary repair reaction. Despite
an overall marked upregulation of VEGF expression in
diabetic glomeruli independent of the degree of injury,
endothelial cell repair was not sufficient to prevent capillary
rarefaction and progressive glomerular sclerosis. This upre-
gulation of VEGF protein during diabetic nephropathy in
man is consistent with two previous studies,16,17 but
controversial to an earlier study.10 While many different cell
types have been shown to produce VEGF as demonstrated in
our study during diabetic nephropathy, VEGF action is
usually thought to predominantly occur on the endothelium.
Nevertheless, no data are available regarding the local activity
of VEGF during any renal disease. Using a monoclonal
antibody that selectively detects a conformational epitope
that is created in the NH2 terminus of VEGF only in
consequence to VEGF receptor binding, we are able to detect
VEGF directly bound to either VEGF-R1 or 2 complex and
thereby can identify the local activity of VEGF during
diabetic renal disease.18,19 The further differentiation of the
binding to VEGF-R1 or 2 cannot be achieved by this method.
In the present study, VEGF is predominantly expressed by
podocytes in glomeruli without any evidence of disease and
becomes positive in other cell types such as endothelial cells,
mesangial cells, and probably monocytes/macrophages dur-
ing the course of diabetic injury, cells for which the
expression of VEGF has been previously demonstrated.9,30
In contrast, the VEGF–VEGF-R antibody showed a more
selective, almost exclusive endothelial staining pattern and
was markedly increased only in glomeruli with mild injury,
but significantly decreased in glomeruli with more severe
changes. Supporting the data regarding VEGF-R activation,
the downstream phosphorylation of Akt was also markedly
enhanced in glomeruli with milder diabetic lesions. This
novel finding indicates a discrepancy between the widely
distributed increase of VEGF expression and its much more
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selective receptor binding/activation in diabetic glomeruli,
indicating the predominant regulation of the endothelial
phenotype during diabetic glomerulopathy. While VEGF is
known as a major regulator of endothelial proliferation,
migration, and survival,31 our data demonstrate the correla-
tion of local VEGF activity but not expression with the
balance of endothelial cell proliferation to apoptosis in
individual diabetic glomeruli and indicate tight regulation
and a major role of VEGF activity during diabetic glomerular
disease. Of course, these biopsy data cannot differentiate
whether VEGF is good or bad for the progression of diabetic
nephropathy. However, these data support the concept that in
quite severe diabetic lesions a lack of local VEGF action is
linked and potentially causative to insufficient capillary
repair and glomerulosclerosis as suggested for many other
glomerular diseases. Whether the increased VEGF activity in
milder lesions indicates a causal ‘bad’ role of VEGF in the
pathophysiology of human diabetic glomerulopathy as
suggested by animal studies or just indicates a stage of
compensatory, increased endothelial repair cannot be deter-
mined before blocking studies in humans may have been
performed. In a study by Kanesaki et al.,32 increased VEGF
gene expression correlated with the presence of extra small
vessels at the vascular pole in human diabetic nephropathy,
suggesting pathological neovascularization. Nevertheless, the
pathologic significance of the appearance of extra small
vessels during diabetic nephropathy is not established and
neither endothelial proliferation nor the glomerular capillary
bed was examined in this study.
Recent experimental studies have shown that the inhibi-
tion of VEGF using VEGF antibodies can ameliorate diabetic
renal changes,5 but a recently published study was not able to
verify these protective effects in a model of lean type II
diabetes.33 Of course, it seems plausible that the ability of
VEGF to induce vascular leakage34 or increased neovascular-
ization can promote pathological processes during the very
early phase of diabetic nephropathy. In contrast, several
experimental studies during other glomerular diseases even
demonstrated a beneficial role of VEGF therapy via
prevention of progressive capillary rarefaction, glomerulo-
sclerosis, and renal scarring.7,8 Considering the elegant
studies by the Quaggin’s group, it becomes clear that VEGF
regulation is extremely tightly controlled within the glomer-
ulus and either local lack or excess of VEGF is detrimental for
the glomerulus.35 Especially in this context of a tight VEGF
regulation, these data of local VEGF expression and activity
need to be interpreted together with the structural changes
and needs for glomerular regeneration during diabetic
disease as pointed out above. Comparing data from
experimental diabetic models with human biopsies is very
problematic, since lesions in experimental models of diabetic
nephropathy are always very mild and may only relate to
human lesions that are so early that they are usually not
represented in a renal biopsy.
In conclusion, this study clearly demonstrates that type II
diabetic nephropathy in man is associated with glomerular
capillary rarefaction probably because of an imbalance of
endothelial cell regeneration/proliferation and endothelial
injury/death. These changes occur despite an overall and
widely distributed glomerular increase of the major angio-
genic cytokine VEGF during diabetic nephropathy. In
contrast, receptor bound VEGF indicating local, predomi-
nantly endothelial VEGF activity was only increased in mild,
but even decreased in severe lesions. Hereby, receptor-bound
VEGF may indicate a relative and local deficiency of VEGF-
driven capillary repair in more severe diabetic lesions.
MATERIALS AND METHODS
Source of tissue
Archival tissues from core needle biopsies performed between the
years 1992 and 2003 at the Klinikum Nuremberg (Nuremberg,
Germany) were used for this study. In all patients, the morpho-
logical diagnosis of diabetic nephropathy was made by the local
pathologist. Each diagnosis was confirmed by the past medical
history of diabetes, thereby patients with type I diabetes were
excluded. Normal human renal tissue (n¼ 10) was obtained from
distant portions of kidneys surgically excised because of the presence
of a localized neoplasm.
Tissue processing and immunohistochemical staining
All biopsies were fixed in 3% paraformaldehyde, embedded in
paraffine, and cut into 4 mm sections for indirect immunoperoxidase
staining according to standard protocols. Negative controls for
immunostaining included either deleting the primary antibody or
substitution of the primary antibody with equivalent concentrations
of an irrelevant murine, goat, or rabbit monoclonal antibody.
Specific rabbit anti-mouse and rabbit anti-goat horseradish
peroxidase-conjugated (all DakoCytomation, Hamburg, Germany)
as well as goat anti-rabbit POD-conjugated (Dianova, Hamburg,
Germany) secondary antibodies were applied followed by color
development with AEC (3-amino-9-ethylcarbazole; DakoCytoma-
tion, a ready-to-use substrate chromogen (red color), or diamino-
benzidine (brown color; DakoCytomation) in the case of double
staining.
To perform immunoperoxidase staining, tissue sections were
incubated with the following primary and secondary antibodies as
indicated at 41C over night.
Antibodies used in this study
Actively proliferating cells where stained using MIB-1, a mouse
monoclonal antibody against the Ki-67 antigen (DakoCytomation;
Hamburg, Germany). The Ki-67 antigen has been shown to be
associated with cell proliferation.36 Renal capillaries were stained
using M-20, a goat monoclonal antibody to PECAM-1/CD31 (Santa
Cruz Biotechnologies, CA, USA). PECAM-1 is a well known
adhesion molecule present on endothelial cells.37 The clone A-20 is
a rabbit polyclonal antibody for the detection of all VEGF isoforms
(Santa Cruz Biotechnologies, CA, USA). VEGF is a major angiogenic
molecule and mitogenic for endothelial cells.4
GV39M is a monoclonal antibody specifically recognizing the
VEGF–VEGF-R complex (VEGF–VEGF-R1 or VEGF–VEGF-R2),
thereby reflecting cells undergoing VEGF-induced receptor activa-
tion.19
For the staining of p-Akt (as a VEGF-R-induced signal), a rabbit
polyclonal antibody raised against a short amino-acid sequence
containing phosphorylated serine at position 473 of human origin
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(Santa Cruz Biotechnologies, CA, USA).38 This antibody also detects
corresponding phosphorylation of Akt 2 and Akt 3.
Quantitative analysis of immunostaining and capillary
rarefaction
For all stainings, all glomeruli were analyzed in a blinded fashion
using a 400-fold magnification. All glomerular results are given
either as cell number or percent positive area per glomerular cross-
section (gcs). Glomerular expression of VEGF and receptor-bound
VEGF were quantified using computer-assisted image analysis
software (MetaVue, Visitron Systems, Puchheim, Germany). Assess-
ment of glomerulosclerosis was done via periodic acid-Schiff stain
stainings. A semiquantitative scoring system from 0 to 4 was applied
where 0 means no sclerosis, 1 means 0–25%, 2 means 25–50%, 3
means 50–75%, and 4 means 75–100% of the glomerular tuft area is
sclerotic. The loss of glomerular capillaries was assessed after
staining for CD31 using an equivalent scoring system from 0 to 4.
The numbers of Ki-67-positive cells as well as p-Akt-positive cells
per glomerular cross-section were counted in all glomeruli. Since
histology of type II diabetic nephropathy is heterogeneous with
mildly and severely injured glomeruli coexisting in the same section,
we evaluated every single glomerulus according to its morphological
integrity as mildly (I), moderately (II), or severely injured (III).
Glomeruli from patients without evidence of renal disease were
grouped as nrd. This evaluation was performed in a second step
independently of the assessment of the specific immunostaining
(e.g. VEGF), but using the same (e.g. VEGF-stained) tissue section.
The degree of glomerular matrix expansion, cellularity, and the
glomerular capillary tuft appearance was used for the injury
classification from I to III according to Table 2. If histological
findings from different injury categories were present within the
same glomerulus, the glomerulus was either assigned to the score
with presence of two out of three positive findings or in the case that
findings from all three categories occurred was scored as II. All
findings where compared to glomeruli from kidneys without
evidence of renal disease (nrd). Assessment of tubulointerstitial
injury was done using periodic acid-Schiff stain stainings and a
semiquantitative scoring system evaluating interstitial fibrosis,
inflammation, tubular atrophy, and dilation. A score of 0 means
normal tubulointerstitium, 1 means injury in less than 25%, 2
means injury up to 50%, and 3 means injury in more than 50% of
the biopsy specimen. To assess peritubular capillary rarefaction, all
kidney biopsies were examined through a 10 10 eyepiece grid
using an original magnification  40 objective. The grid covers an
area of 0.0625 mm2 at this magnification. Each square that
contained no CD31-positive capillary was counted. This scoring
system thus inversely reflects peritubular capillary rarefaction,
whereby higher values indicate loss of capillaries with a maximum
value of 100.39
Immunohistochemical double staining
To determine the number of proliferating endothelial cells, double
immunostaining for Ki-67/MIB, a marker of cell proliferation, and
PECAM/CD31, a endothelial cell-specific marker was performed as
described previously.40 The number of proliferating endothelial cells
was evaluated by counting the number of cells that stained for both
MIB (red) and PECAM (brown) as MIBþ /PECAMþ cells,
respectively, and was expressed as a mean7s.d. per glomerular
cross-section. In parallel, every glomerulus was evaluated using the
classification system for glomerular injury (Table 2).
Terminal deoxynucleotidyl transferase-mediated dUTP-biotin
nick end labelling assay
Apoptotic cells were detected by the terminal deoxynucleotidyl
transferase-mediated dUTP-biotin nick end labeling assay as
described previously,41 counted in every glomerulus and given as
the total number per glomerular cross-section. In parallel, every
glomerulus was evaluated using the scoring system for glomerular
injury (Table 2).
Clinical records
For the day of biopsy, the following data were collected from the
patients corresponding clinical record: age, male/female ratio,
duration of diabetes, proteinuria, albuminuria, presence of retino-
pathy, presence of diabetic neuropathy, presence of hypertension,
HbA1c level, serum creatinine, and urea.
Statistical analysis
All values are expressed as mean7s.d. Statistical significance
(defined as a P of less than 0.05) was evaluated using the
Mann–Whitney U-test. Correlations were calculated using Pearson’s
algorithm. All statistical tests were performed using SPSS 12.0 (SPSS
Inc., Chicago, IL, USA).
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